Evidence map›Paper›PMID 29846872›Full record

ArticleNeuromolecular medicine2018

Withania somnifera as a Potential Anxiolytic and Anti-inflammatory Candidate Against Systemic Lipopolysaccharide-Induced Neuroinflammation.

Muskan Gupta, Gurcharan Kaur

Abstract read
PubMed Publisher
In one paragraph

Article in Neuromolecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
5.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Antibacterial and Immunomodulatory Effects ofInternational journal of molecular sciences · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. A Proton Magnetic Resonance Spectroscopy (International journal of molecular sciences · 2025
    Article
  9. Article
  10. Emerging Vistas for the NutraceuticalPharmaceuticals (Basel, Switzerland) · 2024
    Review
  11. Review
  12. Article
  13. The benefits of ashwagandha (Frontiers in nutrition · 2024
    Review
  14. Review
  15. AshwagandhaPharmaceutics · 2023
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Muskan GuptaMedical Biotechnology Laboratory, Department of Biotechnology, Guru Nanak Dev University, Amritsar, Punjab, 143005, India.
Gurcharan KaurMedical Biotechnology Laboratory, Department of Biotechnology, Guru Nanak Dev University, Amritsar, Punjab, 143005, India. kgurcharan.neuro@yahoo.com.
Guru Nanak Dev University · IN

Funding

Department of Biotechnology, Ministry of Science and Technology BT/PR12200/MED/30/1439/2014
6 · The paper itself

Abstract

Reactive gliosis, microgliosis, and subsequent secretion of various inflammatory mediators like cytokines, proteases, reactive oxygen, and nitrogen species are the suggested key players associated with systemic inflammation-driven neuroinflammation and cognitive impairments in various neurological disorders. Conventionally, non-steroidal anti-inflammatory drugs are prescribed to suppress inflammation but due to their adverse effects, their usage is not well accepted. Natural products are emerging better therapeutic agents due to their affordability and inherent pleiotropic biological activities. In Ayurveda, Ashwagandha (Withania somnifera) is well known for its immunomodulatory properties. The current study is an extension of our previous report on in vitro model system and was aimed to investigate anti-neuroinflammatory potential of water extract from the Ashwagandha leaves (ASH-WEX) against systemic LPS-induced neuroinflammation and associated behavioral impairments using in vivo rat model system. Oral feeding of ASH-WEX for 8 weeks significantly ameliorated the anxiety-like behavior as evident from Elevated plus maze test. Suppression of reactive gliosis, inflammatory cytokines production like TNF-α, IL-1β, IL-6, and expression of nitro-oxidative stress enzymes like iNOS, COX2, NOX2 etc were observed in ASH-WEX-treated animals. NFκB, P38, and JNK MAPKs pathways analysis showed their involvement in inflammation suppression which was further confirmed by inhibitor studies. The current study provides first ever preclinical evidence and scientific validation that ASH-WEX exhibits the anti-neuroinflammatory potential against systemic LPS-induced neuroinflammation and ameliorates associated behavioral abnormalities. Aqueous extract from Ashwagandha leaves and its active phytochemicals may prove to be promising candidates to prevent neuroinflammation associated with various neuropathologies.

Indexed as

PhytotherapyAnimalsAnti-Anxiety AgentsAnti-Inflammatory Agents, Non-SteroidalAnxietyCell LineCytokinesEncephalitisGliosisLipopolysaccharidesMaleMAP Kinase Signaling SystemMicrogliaNF-kappa Bp38 Mitogen-Activated Protein KinasesPlant ExtractsAnti-Anxiety AgentsAnti-Inflammatory Agents, Non-SteroidalCytokinesLipopolysaccharidesNF-kappa Bp38 Mitogen-Activated Protein KinasesPlant ExtractsAnxiety-like behaviorAshwagandhaInflammatory cytokinesLipopolysaccharideNeuroinflammationReactive gliosis

Identifiers

PMID29846872
OpenAlexW2807215656

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.